In The News,
Lindsay Bealor Greenleaf discusses the administration’s proposed Part B drug model with Fierce Healthcare
[el-text]
Written by Paige Minemyer
***excerpt***
Concerns about transparency would extend to Part B if HHS wants to pursue a PBM-esque approach there, Lindsay Bealor Greenleaf, director of ADVI, told Fierce Healthcare.
“It is interesting—the idea of inserting new middlemen into the process, when the administration has raised serious concerns of the role of middlemen on the Part D side of the benefit,” she said.
***end excerpt***
***
[/el-text]